WallStreetZenWallStreetZen

NASDAQ: SLRN
Acelyrin Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SLRN

Based on 3 analysts offering 12 month price targets for Acelyrin Inc

Min Forecast
$3.00+31.58%
Avg Forecast
$7.33+221.62%
Max Forecast
$13.00+470.18%

Should I buy or sell SLRN stock?

Based on 3 analysts offering ratings for Acelyrin Inc.

Buy
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SLRN stock forecasts and price targets.

SLRN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-07
lockedlocked$00.00+00.00%2025-01-07
lockedlocked$00.00+00.00%2024-12-11

1 of 1

Forecast return on equity

Is SLRN forecast to generate an efficient return?

Company
-25.27%
Industry
153.19%
Market
81.87%
SLRN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SLRN forecast to generate an efficient return on assets?

Company
-23.58%
Industry
36.07%
SLRN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SLRN earnings per share forecast

What is SLRN's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.01
Avg 2 year Forecast
-$1.67
Avg 3 year Forecast
-$1.25

SLRN revenue forecast

What is SLRN's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$8.0M
Avg 2 year Forecast
$54.0M
Avg 3 year Forecast
$117.0M

SLRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLRN$2.28$7.33+221.62%Buy
ATXS$4.11$24.50+496.11%Buy
THRD$5.15$5.00-2.91%Hold
CDTX$20.69$38.00+83.71%Strong Buy
HUMA$1.45$19.00+1,210.34%Strong Buy
View Top Biotech Stocks

Acelyrin Stock Forecast FAQ

Is Acelyrin Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: SLRN) stock is to Buy SLRN stock.

Out of 3 analysts, 1 (33.33%) are recommending SLRN as a Strong Buy, 0 (0%) are recommending SLRN as a Buy, 2 (66.67%) are recommending SLRN as a Hold, 0 (0%) are recommending SLRN as a Sell, and 0 (0%) are recommending SLRN as a Strong Sell.

If you're new to stock investing, here's how to buy Acelyrin stock.

What is SLRN's earnings growth forecast for 2025-2027?

(NASDAQ: SLRN) Acelyrin's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Acelyrin's earnings in 2025 is -$248,226,000.On average, 3 Wall Street analysts forecast SLRN's earnings for 2025 to be -$202,094,462, with the lowest SLRN earnings forecast at -$241,703,647, and the highest SLRN earnings forecast at -$158,114,469. On average, 2 Wall Street analysts forecast SLRN's earnings for 2026 to be -$168,185,455, with the lowest SLRN earnings forecast at -$202,426,805, and the highest SLRN earnings forecast at -$133,944,104.

In 2027, SLRN is forecast to generate -$125,887,316 in earnings, with the lowest earnings forecast at -$125,887,316 and the highest earnings forecast at -$125,887,316.

What is SLRN's revenue growth forecast for 2027-2029?

(NASDAQ: SLRN) Acelyrin's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Acelyrin's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast SLRN's revenue for 2027 to be $805,678,824, with the lowest SLRN revenue forecast at $805,678,824, and the highest SLRN revenue forecast at $805,678,824. On average, 1 Wall Street analysts forecast SLRN's revenue for 2028 to be $5,438,332,062, with the lowest SLRN revenue forecast at $5,438,332,062, and the highest SLRN revenue forecast at $5,438,332,062.

In 2029, SLRN is forecast to generate $11,783,052,801 in revenue, with the lowest revenue forecast at $11,783,052,801 and the highest revenue forecast at $11,783,052,801.

What is SLRN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SLRN) forecast ROA is -23.58%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is SLRN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year SLRN price target, the average SLRN price target is $7.33, with the highest SLRN stock price forecast at $13.00 and the lowest SLRN stock price forecast at $3.00.

On average, Wall Street analysts predict that Acelyrin's share price could reach $7.33 by Jan 7, 2026. The average Acelyrin stock price prediction forecasts a potential upside of 221.62% from the current SLRN share price of $2.28.

What is SLRN's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SLRN) Acelyrin's current Earnings Per Share (EPS) is -$2.50. On average, analysts forecast that SLRN's EPS will be -$2.01 for 2025, with the lowest EPS forecast at -$2.40, and the highest EPS forecast at -$1.57. On average, analysts forecast that SLRN's EPS will be -$1.67 for 2026, with the lowest EPS forecast at -$2.01, and the highest EPS forecast at -$1.33. In 2027, SLRN's EPS is forecast to hit -$1.25 (min: -$1.25, max: -$1.25).

What is SLRN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SLRN) forecast ROE is -25.27%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.